NCT06568172 2026-05-13Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin CancerNational Cancer Institute (NCI)Phase 3 Suspended420 enrolled